Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Insulex R vs Humulin R PK/PD in Healthy Subjects
NCT07364669Phase 1Completed
- Sponsor
- PiSA Farmacéutica
- Start
- Oct 2024
- Primary completion
- Feb 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of insulin icodec in diabetes mellitus (DM) (2 arms), sponsored by PiSA Farmacéutica. Primary endpoints: Area Under the Insulin Concentration-Time Curve from 0 to 12 hours, Maximum Insulin Concentration at 12 hours and 2 more. Started Oct 2024; status: completed.
02
Drugs
insulin icodec
03
Conditions
diabetes mellitus (DM)
Beyond the preview
Go deeper on NCT07364669.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07364669.